Trial Profile
Phase I, double-blind, placebo-controlled study of safety, tolerability and short-term efficacy of LY2409021 in patients with type 2 diabetes mellitus treated with diet and exercise or metformin.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 23 May 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 23 May 2012 Actual initiation date (March 2008) and trial locations added as reported by ClinicalTrials.gov.
- 23 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01606397).